0 4 8 12 16 20 24 28 32 36 40 44 48 -250 -200 -150 -100 -50 0 Aflibercept Q8W (n=281) Tarcocimab Q4W (n=276) Observed values. OCT: optical coherence tomography; CST: central subfield thickness. -117 (114) -109 (121) Week 48 (SD) Mean Change in OCT CST Over Time In the wet AMD DAYLIGHT Phase 3 Study Week μm Comparable potency Immediacy gap Did this 3x-longer durability come at a cost? 23 • Immediacy seemed to be the cost . In the wet AMD DAYLIGHT Phase 3 study with the pre-change tarcocimab formulation, a deficit was seen in the loading phase, in the “immediacy” of the effect. After the loading phase, the drying potential or “potency” was comparable to aflibercept Tarcocimab Q4W (n=276), pre-change formulation Aflibercept Q8W (n=281)